A Serious Risk: Excessive and Inappropriate Antipsychotic Prescribing
Recommend Documents
hydrophilic, narrow therapeutic drugs such as lithium and digoxin for which ... with a possible decreased clinical response to beta-blockers and beta-agonists.
May 3, 2018 - O'connor MN, Gallagher P, O'mahony D. Inappropriate prescribing. ... O'mahony D, O'sullivan D, Byrne S, O'connor MN, Ryan C, Gallagher P.
Jan 10, 2014 - Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ ... Hajjar ER, Cafiero AC, Hanlon JT (2007) Polypharmacy in elderly patients.
Sep 7, 2006 - drugs.3-10 These studies prompted the 2002 call by the Secretary for Health and ... Assurance convened an expert consensus panel and, using a modified delphi ... Set (HEDIS) to measure the quality of prescribing for the elderly. ... Cen
years, with good evidence that both typical and atypical agents are effective in the treatment of .... In comparison, atypical antipsychotics are associated.
... and Therapeutics,Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland ... Corresponding author: Frank Moriarty, [email protected] ... Numbe r of pa rticipa nts. 0. 5. 10. 15. 20. Number of PIPs. IADL impairment.
A Serious Risk: Excessive and Inappropriate Antipsychotic Prescribing
A Serious Risk: Excessive and Inappropriate Antipsychotic Prescribing
Mesut Cetin
Bulletin of Clinical Psychopharmacology 2014;24(1):1-4
Although antipsychotics are known to be capable of effectively treating many mental disorders when used appropriately, misuse and/or purposeless use of these agents, especially in the long term, may place the patients at serious risk1-7. As a matter of fact, a comprehensive study by Khan, et al. revealing the association of psychotropic agents with increased mortality has been published recently1. This study covered in detail 92,542 patients recruited for trials sponsored by pharmaceutical companies for FDA indication approval programs, in particular for treatment of schizophrenia, depression, bipolar disorder and anxiety, or for FDA approval for maintenance treatment of attention deficit and hyperactivity disorder. This population corresponded to 47 acute, placebo controlled psychopharmacology trials and safety extension trials conducted between 1990 and 2011. In this group of patients, death risk was found to be significantly higher and associated with the 24 psychiatric diagnosis (χ = 1.760, p
